FDA Approves Lyrfigtu for FGFR2-Altered Cholangiocarcinoma

The U.S. Food and Drug Administration has approved Lyrfigtu (lirafugratinib) as a treatment option for certain patients with cholangiocarcinoma, a rare cancer that develops in the bile ducts. The approval applies to patients whose tumors have an FGFR2 fusion or another qualifying rearrangement.

Announced by Elevar Therapeutics on September 23, 2026, the decision adds another targeted treatment option for people with this molecular form of bile duct cancer. Cholangiocarcinoma is relatively uncommon, with about 8,000 new cases diagnosed in the United States each year, according to information cited in the company announcement.

What Is Lyrfigtu?

Lyrfigtu, also known by its generic name lirafugratinib and its development name RLY-4008, is an oral small-molecule drug designed to selectively inhibit fibroblast growth factor receptor 2, or FGFR2.

FGFR2 belongs to a family of receptor tyrosine kinases involved in cellular signaling. Alterations involving FGFR2 can contribute to the development and growth of certain cancers. Lyrfigtu is designed to target FGFR2 while limiting activity against other members of the FGFR family.

The drug is intended for a molecularly defined group of patients rather than everyone diagnosed with cholangiocarcinoma. This makes genomic or molecular testing important for identifying patients whose tumors contain an FGFR2 fusion or rearrangement that could make them candidates for targeted therapy.

Clinical Trial Results Behind the Approval

The FDA approval was supported by findings from the Phase 1/2 ReFocus clinical trial, identified as NCT04526106.

According to Elevar Therapeutics, Lyrfigtu produced a confirmed objective response rate of 46% among patients in the proposed indication. Objective response rate measures the proportion of patients whose tumors shrink by a predefined amount during treatment.

The median duration of response was 11.8 months. Median progression-free survival, which represents the length of time patients lived without their cancer progressing, was reported at 11.3 months. The 12-month progression-free survival rate was 49.2%.

These findings should be understood in the context of the patient population and design of the ReFocus study. Results from a clinical trial do not guarantee that every patient receiving the drug will experience the same response or duration of benefit.

Why FGFR2 Testing Matters in Cholangiocarcinoma

The approval illustrates the growing role of precision medicine in cancer care.

Rather than selecting treatment solely according to where a cancer originates, clinicians can increasingly use molecular characteristics of a tumor to identify therapies designed for specific alterations.

FGFR2 fusions and rearrangements represent one such actionable molecular feature in cholangiocarcinoma. Because Lyrfigtu is approved for an FGFR2-defined population, determining the molecular profile of a patient's tumor can influence treatment planning.

Experts quoted in Elevar's announcement also highlighted the role of molecular testing in connecting eligible patients with targeted therapies.

Lyrfigtu Safety and Side Effects

Like other cancer treatments, Lyrfigtu carries potentially significant risks and requires medical monitoring.

One important warning involves ocular toxicity. Lyrfigtu can cause retinal pigment epithelial detachment, or RPED, which may produce symptoms such as blurred vision.

Among 385 patients who received Lyrfigtu, RPED occurred in 31%, including Grade 3 events in 1.8%. The median time to the first occurrence was 57 days. The prescribing safety information recommends ophthalmological examinations before treatment and regular eye monitoring during therapy.

Dry eye was reported in 38% of patients, while corneal toxicity or keratitis occurred in 11%.

Another important risk is hyperphosphatemia, or elevated phosphate levels in the blood. This occurred in 21% of patients, with a median onset of 15 days. The safety information recommends monitoring serum phosphate throughout treatment.

Lyrfigtu can also cause fetal harm based on its mechanism of action and findings from animal studies. Patients of reproductive potential should discuss contraception recommendations and pregnancy risks with their healthcare professionals.

Other Adverse Reactions

Serious adverse reactions occurred in 32% of patients included in the safety data. Serious reactions reported in at least 2% of patients included infection, pneumonia, fatigue and hemorrhage. One fatal adverse reaction involving hemorrhage was reported.

Common adverse reactions included nail toxicity, hand-foot syndrome, stomatitis, hair loss, dry eye, dry mouth, fatigue, changes in taste, constipation, dry skin, infection, rash, abdominal pain, blurred vision, diarrhea, musculoskeletal pain, nausea and decreased appetite.

Laboratory abnormalities were also reported, including changes in phosphate, liver enzymes, creatinine, hemoglobin, sodium, lymphocytes, bilirubin, platelets, glucose and other measurements.

Patients considering treatment should discuss the full prescribing information, potential benefits, risks, drug interactions and required monitoring with their oncology team.

When Will Lyrfigtu Be Available?

Elevar Therapeutics stated that Lyrfigtu is expected to become available to patients in the United States by the fourth quarter of 2026.

The company is also evaluating lirafugratinib in additional clinical development programs involving other FGFR2-altered solid tumors. These investigational uses should not be confused with FDA-approved indications. Any additional indication would require appropriate clinical evidence and regulatory review before approval.

What the FDA Approval Means

The approval of Lyrfigtu expands the targeted treatment landscape for patients with FGFR2-altered cholangiocarcinoma. It also reinforces a broader shift in oncology toward treatments selected using the molecular characteristics of individual tumors.

For patients, one practical implication is the importance of discussing biomarker testing with an oncology specialist. Identifying an FGFR2 fusion or rearrangement may help determine whether an FGFR2-targeted therapy is an appropriate treatment option.

At the same time, treatment decisions need to consider much more than a single biomarker. Previous therapies, cancer stage, overall health, potential adverse effects and individual treatment goals can all influence the choice of therapy.

Source

Elevar Therapeutics regarding the FDA approval of Lyrfigtu (lirafugratinib), including clinical results and safety information supplied in that announcement.

Disclaimer

This article is provided for informational and educational purposes only and is not intended as medical advice, diagnosis or a recommendation for any specific treatment. Drug indications, safety information and prescribing recommendations may change over time. Patients should consult a qualified healthcare professional and review the current FDA-approved prescribing information before making treatment decisions. Individual outcomes can vary, and clinical trial results do not guarantee the same results for every patient.